Consequently, this amplifies the harmful effects of natural killer 226 cells via the interplay of CD92, CD155, and the TIGIT co-inhibitory receptor, which in turn facilitates the cancer-fighting capabilities of EC cells and produces twofold anti-cancer impacts (97). This evidence concerns the gene SLC44A1 and cancer.